精神病早期与临床高风险阶段的突触密度
这项横断面研究在三级精神专科医院纳入16例首发精神病患者、17例临床高风险个体和16名健康对照,用[18F]SynVesT-1 PET量化突触密度。结果显示组间突触密度存在显著差异,大麻使用者突触密度较低,且较低突触密度与更严重的阴性症状相关。
要点
- 首发精神病与临床高风险个体均存在突触密度降低,且与阴性症状严重程度相关。
- 大麻使用与更低的突触密度相关。
- SV2A结合电位与神经突密度指数显著相关。
核心结论
- 本研究发现在精神病早期及其高风险阶段已存在突触密度降低,并与阴性症状相关。
- SV2A对精神病和临床高风险个体阴性症状的意义有待进一步研究。
- 未来研究应纵向探究大麻使用对临床高风险个体突触密度的影响。
研究设计与样本
- 横断面研究,于2021年7月至2023年10月在三级精神专科医院开展。
- 纳入16例未用药或极少暴露抗精神病药的首发精神病患者、17例临床高风险个体和16名健康对照,尿液药物筛查干净(大麻除外)。
- 用动态90分钟[18F]SynVesT-1正电子发射断层扫描在个体磁共振图像 delineated 的优先脑区感兴趣区中量化突触密度。
- 用尿液药物筛查确认大麻使用,用扩散加权磁共振估算神经突密度以评估灰质微结构。
主要发现
- 共纳入49名参与者:首发精神病组平均年龄26.1(标准差4.6)岁,男9例女7例;临床高风险组平均年龄21.2(标准差3.5)岁,男8例女9例;健康对照组平均年龄23.4(标准差3.6)岁,男7例女9例。
- 突触密度组间差异显著(F2,273=4.02,P=.02,Cohen F=0.17;感兴趣区:F5,273=360.18,P<.01,Cohen F=2.55),并存在组别×感兴趣区交互作用(F10,273=2.67,P<.01,Cohen F=0.32)。
- 大麻使用者的突触密度更低(F1,272=5.31,P=.02,Cohen F=0.14)。
- 跨组较低突触密度与更严重的阴性症状相关(阳性和阴性症状量表阴性分:F1,81=4.31,P=.04,Cohen F=0.23;精神病风险症状量表阴性分:F1,90=4.12,P=.04,Cohen F=0.21)。
- SV2A结合电位与神经突密度指数显著相关(F1,138=6.76,P=.01,Cohen F=0.22)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Synaptic dysfunction is involved in schizophrenia pathophysiology. However, whether in vivo synaptic density is reduced in early stages of psychosis, including its high-risk states, remains unclear. OBJECTIVE: To investigate whether synaptic density (synaptic vesicle glycoprotein 2A [SV2A] binding potential) is reduced in first-episode psychosis (FEP) and in clinical high risk (CHR) and investigate the effect of cannabis use on synaptic density and examine its relationship with psychotic symptoms and gray matter microstructure across groups. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study was performed in a tertiary care psychiatric hospital from July 2021 to October 2023. Participants were patients with antipsychotic-free or minimally exposed FEP or CHR and healthy controls with a clean urine drug screen (except cannabis). MAIN OUTCOMES AND MEASURES: Synaptic density was quantified with dynamic 90-minute [18F]SynVesT-1 positron emission tomography (PET) scans across prioritized brain regions of interest (ROIs) delineated in individual magnetic resonance images (MRIs). Cannabis use was confirmed with urine drug screens. Gray matter microstructure was assessed using diffusion-weighted MRI to estimate neurite density. RESULTS: A total of 49 participants were included, including 16 patients with FEP (mean [SD] age, 26.1 [4.6] years; 9 males and 7 females), 17 patients at CHR (mean [SD] age, 21.2 [3.5] years; 8 males and 9 females), and 16 healthy controls (mean [SD] age, 23.4 [3.6] years; 7 males and 9 females). Synaptic density was significantly different between groups (F2,273 = 4.02, P = .02, Cohen F = 0.17; ROI: F5,273 = 360.18, P < .01, Cohen F = 2.55) with a group × ROI interaction (F10,273 = 2.67, P < .01, Cohen F = 0.32). Synaptic density was lower in cannabis users (F1,272 = 5.31, P = .02, Cohen F = 0.14). Lower synaptic density across groups was associated with more negative symptoms (Positive and Negative Syndrome Scale negative scores: F1,81 = 4.31, P = .04, Cohen F = 0.23; Scale of Psychosis-Risk Symptoms negative scores: F1,90 = 4.12, P = .04, Cohen F = 0.21). SV2A binding potential was significantly associated with neurite density index (F1,138 = 6.76, P = .01, Cohen F = 0.22). CONCLUSIONS AND RELEVANCE: This study found that synaptic density reductions were present during the early stages of psychosis and its risk states and associated with negative symptoms. The implications of SV2A for negative symptoms in psychosis and CHR warrant further investigation. Future studies should investigate the impact of cannabis use on synaptic density in CHR longitudinally.
引用
- Blasco MB, Nisha Aji K, Ramos-Jiménez C, et al. Synaptic Density in Early Stages of Psychosis and Clinical High Risk. JAMA Psychiatry. 2025. PMID: 39535765. doi:10.1001/jamapsychiatry.2024.3608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。